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ARTICLE
Inhibition of vascular calcification by inositol
phosphates derivatized with ethylene glycol
oligomers
Antonia E. Schantl1,8, Anja Verhulst2,8, Ellen Neven2, Geert J. Behets 2, Patrick C. D’Haese2, Marc Maillard 3,
David Mordasini3, Olivier Phan3, Michel Burnier3, Dany Spaggiari4, Laurent A. Decosterd 4,
Mark G. MacAskill 5, Carlos J. Alcaide-Corral5, Adriana A.S. Tavares5, David E. Newby5, Victoria C. Beindl1,
Roberto Maj6, Anne Labarre7, Chrismita Hegde7, Bastien Castagner7, Mattias E. Ivarsson6,9* &
Jean-Christophe Leroux 1,9*
Myo-inositol hexakisphosphate (IP6) is a natural product known to inhibit vascular calcifi-
cation (VC), but with limited potency and low plasma exposure following bolus adminis-
tration. Here we report the design of a series of inositol phosphate analogs as crystallization
inhibitors, among which 4,6-di-O-(methoxy-diethyleneglycol)-myo-inositol-1,2,3,5-tetrakis
(phosphate), (OEG2)2-IP4, displays increased in vitro activity, as well as more favorable
pharmacokinetic and safety profiles than IP6 after subcutaneous injection. (OEG2)2-IP4
potently stabilizes calciprotein particle (CPP) growth, consistently demonstrates low
micromolar activity in different in vitro models of VC (i.e., human serum, primary cell cul-
tures, and tissue explants), and largely abolishes the development of VC in rodent models,
while not causing toxicity related to serum calcium chelation. The data suggest a mechanism
of action independent of the etiology of VC, whereby (OEG2)2-IP4 disrupts the nucleation
and growth of pathological calcification.
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Vascular calcification (VC) is the consequence of patholo-gical deposition of calcium phosphate mineral in softtissues1. Symptoms and associated risks vary depending
on the location (artery vs. valve, tunica media vs. intima) at which
calcification occurs, as well as on its nature (nano- vs. micro- vs.
macrocalcification)2,3. Clinical consequences may include aortic
stiffening4, occlusive lesions (e.g., atherosclerotic plaques)5, or
aortic valve stenosis6,7, ultimately resulting in an increased risk
for cardiovascular morbidity and mortality8.
In chronic kidney disease (CKD), mineral homeostasis is dis-
turbed due to impaired renal function9, and cardiovascular
complications are the leading cause of death in these patients10,11.
Furthermore, VC is also a hallmark of a number of orphan dis-
eases, such as pseudoxanthoma elasticum and generalized arterial
calcification of infancy12,13. To date, there are no approved
pharmacological interventions for the direct prevention or
treatment of VC. The etiology of VC is complex and multi-
factorial. Several factors govern the calcification process in the
vessel wall microenvironment, acting to promote or inhibit cal-
cification in conjunction with local precipitation of calcium and
phosphate8. The most important endogenous calcification inhi-
bitors include serum fetuin-A14, matrix Gla protein15, and pyr-
ophosphate (PPi)16. Most drug candidates currently under clinical
investigation for VC (e.g., bisphosphonates, phosphate-binders,
vitamin K, or magnesium) act by correcting the imbalance of
calcification promoters (i.e., hyperphosphatemia) and inhibitors
in VC-affected individuals. However, these drug candidates have
yet to prove their efficacy in cardiovascular disease patients17,18.
Under non-pathological conditions, surges of plasma phos-
phate or calcium, or local drops in the concentration of circu-
lating calcification inhibitors are buffered by acidic serum
proteins, notably fetuin-A, via the formation of colloidal calci-
protein particles (CPPs)19. Primary CPPs (CPP1) are spherical
complexes of amorphous calcium and phosphate with fetuin-A
with a hydrodynamic radius (Rh) of less than 100 nm20. The
nanoparticles formed prevent precipitation of calcium and
phosphate (i.e., hydroxyapatite formation)21. In the pathology of
VC, the system becomes depleted of factors delaying calcification
propensity and the balance between CPP1 formation and
absorption is distorted22. As a consequence, larger (Rh > 100 nm),
crystalline, and spindle-shaped CPPs (secondary CPPs, CPP2s)
emerge20,23. Primary and secondary CPPs are predominantly
cleared by liver sinusoidal endothelial cells and liver Kupffer cells,
respectively. Scavenger receptor A is a major endocytosis receptor
for CPP2s but not for CPP1s, indicating separate clearance
pathways24. Native CPPs in fresh plasma are smaller and lower in
density than synthetic CPP1 and CPP229. In CKD, CPPs are
likely involved in the pathology of VC25,26. Serum CPP levels
increase with decline of renal function and correlate with cor-
onary artery calcification score, arterial stiffness, serum phos-
phate, inflammation, and procalcific factors27,28. Moreover, in
patients with advanced CKD, the Rh of CPP2 was associated with
VC29. The fact that CPP2s have the ability to induce VSMC
calcification in vitro has raised the hypothesis that CPP2s may
present a valid therapeutic target in VC30.
In patients with VC, a continuum of calcification typically
occurs with evidence of nano-, micro-, and macrocalcification,
which follows a common pathophysiology. Scanning electron
microscopy of various diseased human aortic valve and arterial
tissues reveals the presence of spherical, crystalline hydro-
xyapatite particles ranging in size from 100 nm to 5 µm31, sug-
gesting that VC may follow a common process independent of
the etiology31,32. Further evidence for the presence of micro-
calcifications comes from positron emission tomography (PET)
imaging of high-risk coronary atherosclerotic plaque33 employing
[18F] sodium fluoride (18F-NaF), a marker of active vascular
micro-calcification34. Subsequently, larger confluent deposits
occur, which are visible on clinical computed tomography scan-
ning35. Macrocalcifications negatively impact cardiovascular tis-
sue (e.g., arterial and valvular stiffening, intima-media
thickening) and hemodynamic parameters (e.g., pulse wave
velocity, aortic valve pressure gradient). As a consequence, the
risk for atherosclerotic events, heart failure, and cardiovascular as
well as all-cause mortality increases35–38.
Myo-inositol hexakisphosphate (IP6) is a ubiquitously
occurring natural product and endogenous intracellular co-
factor in mammalian cells with putative functions in the areas
of vesicle recycling and nuclear transport39. It inhibits the
formation and growth of hydroxyapatite microcrystals in soft
tissues when administered parenterally40,41. Completed phase
II studies in hemodialysis patients with calciphylaxis or cor-
onary artery calcifications, respectively, showed good safety,
tolerability, as well as encouraging efficacy42–44. IP6 is injected
intravenously through the dialysis machine during hemodia-
lysis sessions to allow it to reach therapeutic exposure despite
its modest potency and short plasma half-life45. Both factors
complicate its development as a chronic ambulatory therapy46.
Given the paucity of data on the properties of IP6 analogs in
this context, this study investigates whether the chemical
modification of IP6 could produce more potent inhibitors with
improved pharmacokinetic (PK) properties that may enable its
administration by a more convenient route. In previous work
from our group, where calcium phosphate nanoparticles for
gene delivery were developed, it was shown that coating of these
particles with conjugates of oligo(ethylene glycol) (OEG)
and myo-inositol pentakisphosphate prevent the rapid size
increase of calcium phosphate nanoparticles47,48. In the present
study, structurally related conjugates are tested in the context of
VC inhibition49. Several OEGylated myo-inositol phosphate
derivatives are synthesized and screened for their ability to
inhibit calcification, as well as for their resistance towards
hydrolysis. The lead candidate is characterized for its efficacy
in primary human vascular smooth muscle cells (VSMCs) and
calcified human cardiovascular tissue explants, its biopharma-
ceutical properties, as well as its in vivo activity in rat models
of VC50. This work identifies a potent OEG-derivatized inositol
phosphate, (OEG2)2-IP4, with a distinct mechanism of action
that may find clinical utility for the prevention and/or
treatment of VC.
Results
Design and synthesis of inhibitors of VC. Initially, OEG12-IP5, a
low molecular weight derivative of the chelator previously used by
our group to stabilize calcium phosphate nanoparticles for
gene delivery purposes47, was synthesized in three steps starting
from 1,3,5-O-methylidyne-myo-inositol (Supplementary Infor-
mation 3.1.1.). It was purified by size-exclusion chromatography
and characterized by proton-1 nuclear magnetic resonance (1H-
NMR) and phosphorus-31 nuclear magnetic resonance (31P-
NMR) spectroscopies (Supplementary Information 5.), and elec-
trospray ionization-mass spectrometry (ESI-MS) (Supplementary
Table 1). Starting from OEG12-IP5, other inhibitors were designed
as follows: (i) increasing the number of linked OEG units while
decreasing that of phosphates (e.g., (OEG)2-IP4 and (OEG)3-IP3)
to study the trade-off between lower charge and increased steric
hindrance, (ii) replacing phosphates by sulfate groups (i.e., OEG11-
IP2S3) to investigate chemical stability towards hydrolysis and to
reduce chelation of soluble Ca2+51, and (iii) reducing OEG
chain length (OEG12, OEG11, OEG7, and OEG2) to study the
influence of the latter on activity (Fig. 1a). Ten compounds,
covering a broad range of chemical modifications, were produced
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or purchased, and details on their synthesis and characterization
are provided in the Supplementary Methods. These compounds
were compared to 12 controls (Fig. 1b).
Drug candidate screening assay. The compounds were ranked
for calcification inhibition activity using a nanoparticle-based test,
developed for risk stratification, which measures the propensity
for calcification in patient serum22. The transformation of
amorphous CPP1s to larger crystalline CPP2s in pooled human
serum was monitored in the presence of inhibitor, and artificially
elevated calcium and phosphate concentrations at 37 °C. The
time, after which 50% of CPP phase transition occurred (T50), was
assessed by time-resolved spectrophotometry at 550 nm (Sup-
plementary Fig. 1a). To rank the compounds’ activity, a T50 vs.
compound concentration plot was generated, and the con-
centration necessary to delay T50 to 350min (c350, at which IP6’s
activity was at half-maximum) was derived from nonlinear curve
fitting (Fig. 2a, Supplementary Figs. 1–3). (OEG11)2-IP4 displayed
an almost 10-fold greater molar activity in delaying serum cal-
cification propensity (c350= 3.8 ± 0.3 µM) than IP6 (c350=
35.0 ± 9.9 µM). Further, as seen in Table 1, (OEG11)2-IP4 was the
most active molecule of all screened functionalized inositol
phosphates and tested controls. However, looking at activity by
unit mass, (OEG2)2-IP4 had an apparent 32% stronger inhibition
than (OEG11)2-IP4 due to its lower molecular weight—an
important consideration for dosing purposes (Table 1). These
data indicate that (i) replacement of two, rather than one or three
phosphates of IP6 by OEG is optimal, (ii) replacement of phos-
phates by sulfates in the OEGylated molecules reduces activity,
and (iii) longer OEG chains increase molar activity but reduce
activity by unit mass. Moreover, molar activity of (OEG2)2-IP4
was approximately six- and twofold higher than pyrophosphate
(PPi) (a strong endogenous inhibitor of VC) and etidronate (a
hydrolysis-resistant analog of PPi), respectively (Table 1, Sup-
plementary Fig. 3).
In vitro characterization. To confirm the screening assay data,
the hydrodynamic diameter of the CPPs was measured by
dynamic light scattering (DLS). In the absence of inhibitors or in
the presence of IP6 (up to 100 µM), the CPP1 size grew from
roughly 150 nm after 1 h to ~1 µm after 3 h of incubation in
serum (Supplementary Fig. 4c, f), indicating transition to CPP2.
The CPP2 size deduced by DLS is slightly larger than the size
derived from transmission electron microscopy (TEM) (Supple-
mentary Figs. 4c and 7a), the latter being in line with previous
work52. (OEG2)2-IP4, added to CPP1s at a final concentration of
30 µM, stabilized particle growth (Supplementary Fig. 4h)29. TEM
revealed the presence of spherical-shaped CPP1s in samples
incubated with 100 µM (OEG2)2-IP4 vs. spindle-shaped CPP2s in
samples containing 100 µM IP6 (Fig. 2b). Corresponding selected
area electron diffraction analysis of CPP with 100 µM IP6 showed
bright spots and well-defined rings, indicating crystalline mate-
rial, whereas the (OEG2)2-IP4-stabilized CPP1s were largely
amorphous. The derived interplanar- or d-spacings for CPP
incubated with IP6 were: d1= 0.287 nm*, d2= 0.369 nm†, and
d3= 0.403 nm, which are in line with reported literature d-spaces










































































































































Fig. 1 Structures of functionalized inositol phosphates and control compounds. a Structure of the series of calcification inhibitors that were synthesized,
with n= 2, 7, 11, and 12 for OEGn-IP5, n= 2, 7, and 11 for (OEGn)2-IP4, n= 11 for OEGn-IP2S3, and n= 2 and 7 for (OEGn)3-IP3. Represented in red is the
backbone structure of the lead inhibitor of this study. b Structures of compounds used as controls, including dephosphorylated (IP5, IP4, IP3, IP2, myo-
inositol) and phosphorylated (myo-inositol trispyrophosphate (ITPP)) IP6 derivatives, myo-inositol hexathiophosphate (IT6), pyrophosphate (PPi), as well
as alendronate and etidronate (non-hydrolyzable analogs of PPi). PEG45-alendronate has been described previously to stabilize calcium phosphate
nanoparticles in vitro48.
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0.52 nm53 (matching d-spaces between samples are indicated with
* and †) and suggest identical material.
A 18F-NaF-based competitive binding assay was developed to
indirectly assess the inhibitor affinity (IC50) to CPPs. The
uptake mechanism of 18F-NaF, a marker of micro-calcification
activity by chemisorption onto hydroxyapatite crystals, is
contingent on the rapid exchange of hydroxyl (OH−) groups
present on the hydroxyapatite surface (Ca5(PO4)3(OH)) by 18F−
to form fluoroapatite (Ca5(PO4)318F)34,54. Similarly to 18F-NaF,
IP6 and (OEG2)2-IP4 are expected to be adsorbed to the
hydroxyapatite core of CPPs. (OEG2)2-IP4 reduced 18F binding
to CPP more efficiently than IP6 (IC50= 0.81 µM, 95% CI [0.48,
1.37] vs. 3.96 µM, 95% CI [2.03, 7.75]), despite the lower
negative charge density, and thus lower Ca2+ chelating ability
of (OEG2)2-IP4 compared to IP6 (Fig. 2c), hence supporting the
hypothesis that the OEG moiety contributes to the activity of
(OEG2)2-IP4. Alendronate showed a comparable CPP-binding
affinity (IC50= 0.90 µM, 95% CI [0.54–1.50]) while having a
twofold lower activity in the calcification propensity assay
(c350= 9.9 ± 1.0 µM). Due to the electrostatic nature of the
interaction of (OEG2)2-IP4 with hydroxyapatite, the binding is
likely reversible. Because of these results and the fact that
clinical trials using bisphosphonates in VC reported important
side effects55, alendronate was not further investigated in
this study.
Since IP6 is highly susceptible to degradation to lower inositol
phosphates due to endogenous phosphatase activity39, the in vitro
stability of selected OEGylated inositol phosphates after exposure to
3-phytase and incubation in enzymatically active human serum was
investigated. Enzymatic hydrolysis of inositol phosphates in buffer
was reduced and delayed by the presence of OEG moieties
compared to IP6 (Fig. 2d), likely due to steric hindrance hampering
enzymatic activity. Protection from phosphate hydrolysis increased
with number, but not with length of conjugated OEG. OEGylated
inositol phosphates retained complete activity in the calcification
propensity assay after a 4.5-h incubation in enzymatically active
serum, as opposed to IP6, with which T50 decreased by 73min from
baseline (Fig. 2e).
All subsequent testing was performed with (OEG2)2-IP4
because it demonstrated comparable stability and molar activity
to (OEG11)2-IP4, but would eventually be administered in vivo at
a lower dose in mass, given its lower molecular weight.
Inhibition of human VSMC calcification. A postulated driving
force for VC at the cellular level are VSMCs, the main cell type of
the tunica media. VSMCs can transdifferentiate towards an
900a
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Fig. 2 In vitro activities of functionalized inositol phosphates. a Compounds were tested in an in vitro serum calcification propensity assay. T50 is defined
as the time at which 50% of CPP1 is transformed to CPP2. The concentration necessary to delay T50 to 350min (dotted line) was used to compare the
compounds’ activities (n= 4 for myo-inositol, n= 6 for (OEG2)2-IP4, and n= 26 for IP6). b Representative TEM images and corresponding selected area
electron diffraction patterns of CPPs, showing the predominant presence of spherical-shaped CPP1s and spindle-shaped CPP2s after incubation with
100 µM (OEG2)2-IP4 and IP6, respectively for 14 h at 37 °C (scale bar= 50 nm). c Competitive 18F-NaF-binding assay to characterize interaction of
compounds with CPPs (n= 3). d Phytase hydrolysis of compounds (n= 3). e Activity in the serum calcification propensity assay after incubation in
enzymatically active human serum for 4.5 h at 37 °C (n= 4). All data are expressed as mean ± s.d. from n independent experiments. Statistical significance
was calculated from a paired Student’s t-test, ***p < 0.001 vs. baseline T50.
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osteoprogenitor cell type under prolonged mineral exposure or
uremic stress, and release vesicles packed with high concentra-
tions of calcium and phosphate serving as nidi for extracellular
matrix calcification56–60.
Incubating primary human VSMCs with (OEG2)2-IP4
(0.01–100 µM) did not lead to any changes in cell viability
(Fig. 3a). The activity of (OEG2)2-IP4 in inhibiting calcification of
VSMCs was then examined using a high-CaP (2.7 mM calcium,
2.5 mM phosphate) medium (Supplementary Fig. 5). Incubation
of VSMCs in high-CaP medium induced cell monolayer
calcification after 5 days (Fig. 3b). Concurrent incubation with
(OEG2)2-IP4 (0.01–100 µM) dose-dependently prevented calcifi-
cation as evidenced from the quantitative measurement of the
calcium content (Fig. 3b), and qualitative staining for calcium
with Alizarin Red (Fig. 3c). The effect became significant from
0.1 µM (OEG2)2-IP4 on, where a 54% reduction in calcification
was observed compared to untreated high-CaP medium-exposed
cells. Calcium deposition was almost completely abrogated above
1 µM (OEG2)2-IP4. IP6 reduced VSMC mineralization by
~50–70% for all doses studied (up to 100 µM). The less efficient
inhibition in calcification may be due to the limited IP6 solubility
in high calcium medium51 or potential extracellular effects (e.g.
protein binding)39. In the present model, cell viability seemed to
be slightly decreased in low-dose treatment groups (0.01 and 0.1
µM (OEG2)2-IP4) vs. high-CaP medium control but this effect
disappeared above 1 µM for (OEG2)2-IP4 and 10 µM for IP6
(Fig. 3d).
CPPs have been implicated in the mineralization paradox of
CKD, and previous in vitro work using synthetic CPP2s suggests
a role in promoting VSMC calcification25,30,61,62 and in reducing
hydroxyapatite mineral stress in macrophages63. Macrophage
accumulation and inflammation coincide with the initial
phase of calcification3. To this end, VSMCs and THP-1-derived
macrophages were exposed to CPP2-supplemented medium.
CPP2 prepared from human serum as described previously61
(Supplementary Figs. 6 and 7), induced a pronounced VSMC
monolayer calcification after 48 h, which was decreased by
(OEG2)2-IP4 in a dose-dependent fashion, and the effect became
significant at 10 µM (Fig. 3e). These results were supported by
Alizarin Red staining (Supplementary Fig. 8). (OEG2)2-IP4
treatment did not reduce VSMC viability in this setup (Fig. 3f).
Incubating VSMCs with CPP1 increased calcium deposition vs.
control, but not significantly, and (OEG2)2-IP4 treatment starting
at 10 µM reduced calcium deposition to the level of control
(Fig. 3g). Both H2O2 (proxy for oxidative stress) and tumor
necrosis factor-alpha (TNF-α) (proxy for inflammatory response)
levels were assayed in the VSMC culture supernatants subsequent
to CPP2 treatment with and without compounds30. However, no
increase in H2O2 nor TNF-α compared to control could be
detected in either assay. For the CPP-induced VSMC calcification
assay (Fig. 3e) a roughly 10-fold higher concentration of
(OEG2)2-IP4 was necessary to achieve similar activity as in the
CaP-induced VSMC calcification assay (Fig. 3b). This may be
explained by a more potent induction of calcification in the CPP-
induced assay, requiring higher (OEG2)2-IP4 concentration to
counteract the procalcific environment. In the CaP assay, low
inhibitor concentration may be sufficient to inhibit crystal
nucleation, whereas for the CPP assay higher inhibitor concen-
trations may be needed to achieve sufficient particle stabilization
by chemisorption of inhibitor onto CPPs. Similar results have
been reported for hydrogen sulfide in the context of VC62,64. In
both the VSMC and macrophage assays, precipitation in culture
medium occurred in treatment groups containing high concen-
trations of IP6 (100 µM) but not with (OEG2)2-IP4 at the same
concentrations (Fig. 3h microscopy images and Supplementary
Fig. 9). This effect is likely due to the strong chelating potential of
IP6 with free ionized serum calcium. Indeed, the combined
treatment of 100 µM IP6 and CPP2 (i) resulted in precipitation
visible to the naked eye in the treatment medium, (ii) significantly
reduced macrophage viability by 24% (Fig. 3i), and (iii) TNFα
(indicator for inflammatory response) release from macrophages
increased 49-fold (Fig. 3h). An increase in the TNFα levels in the
cell culture supernatants was not observed for (OEG2)2-IP4 with
(Fig. 3h) and without (Supplementary Fig. 10) combined CPP2
treatment.
Target engagement in calcified human explants. To investigate
(OEG2)2-IP4 interaction with calcified tissues in a clinically
relevant context, a competitive binding assay using 18F-NaF was
applied on severely calcified human femoral arteries and native
aortic valves ex vivo. The tissue explants were incubated with
(OEG2)2-IP4 at a concentration inhibiting 90% 18F-NaF binding
(IC90= 8.6 μM), as assessed in Fig. 2c. First, 18F-NaF uptake was
measured on tissue samples treated with vehicle (human serum)
and thereafter, using the same tissue samples, treated with
(OEG2)2-IP4 in serum. Compared to the vehicle controls, results
showed a significant reduction of 18F-NaF uptake in calcified
human femoral arteries (−38%) (Fig. 3j, l) as well as in calcified
leaflets from native human aortic valves (−33%) (Fig. 3k, m).
OEGylation improves the PK profile of inositol phosphates.
The plasma half-life (t1/2) of IP6 is short (8 min) after intravenous
(i.v.) bolus administration in rats45,65, and values of 27 and 54
min after a 4-h i.v. infusion have been reported in hemodialyzed
patients and healthy volunteers, respectively43. Therefore, the PK
profile of (OEG2)2-IP4 was assessed in healthy and uremic rats
and compared to that of IP6. At 10 mg/kg, (OEG2)2-IP4 displayed
an almost 10-fold increase in plasmatic t1/2 vs. IP6 after i.v. bolus
Table 1 Activities of compounds in the screening assay.
Compound Concentration at T50= 350min
mean ± s.d. (n)
µM mg/L
Inositol phosphate derivatives
OEG2-IP5 7.9 ± 2.7 (3) 7.1 ± 2.4 (3)
OEG7-IP5 6.7 ± 0.9 (3) 7.6 ± 1.0 (3)
OEG11-IP5 5.3 ± 0.7 (3) 6.8 ± 0.9 (3)
OEG12-IP5 4.9 ± 0.6 (5) 6.6 ± 0.9 (5)
(OEG2)2-IP4 4.9 ± 0.8 (6) 4.3 ± 0.7 (6)
(OEG7)2-IP4 4.5 ± 0.4 (3) 6.0 ± 0.6 (3)
(OEG11)2-IP4 3.8 ± 0.3 (3) 6.3 ± 0.6 (3)
OEG11-IP2S3 18.6 ± 1.9 (5) 22.9 ± 2.3 (5)
(OEG2)3-IP3 7.1 ± 0.9 (3) 5.4 ± 0.7 (3)
(OEG7)3-IP3 9.4 ± 0.6 (3) 14.3 ± 1.0 (3)
Inositol controls
myo-Inositol >100 (4) >18.0 (4)
IP2 35.0 ± 7.7 (3) 15.0 ± 3.3 (3)
IP3 18.6 ± 3.1 (3) 10.2 ± 1.7 (3)
IP4 19.5 ± 0.7 (3) 13.2 ± 0.5 (3)
IP5 13.2 ± 1.3 (3) 10.5 ± 1.0 (3)
IT6 14.4 ± 0.3 (3) 36.14 ± 0.24 (3)
ITPP >100 (4) >60.6 (4)
Known inhibitors of calcification
IP6 35.0 ± 9.9 (26) 30.9 ± 8.7 (26)
Magnesium citrate >100 (3) >21.4 (3)
PPi 27.4 ± 2.8 (3) 7.3 ± 0.8 (3)
Etidronate 10.5 ± 1.1 (4) 2.6 ± 0.3 (4)
Alendronate 9.9 ± 1.0 (6) 3.2 ± 0.3 (6)
Others
PEG-alendronate 12.3 ± 3.0 (3) 28.1 ± 6.9 (3)
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injection into male rats (t1/2= 78 ± 32 vs. t1/2= 8 ± 2 min,
respectively) (Fig. 4a, b). The apparent volumes of distribution
were low with 234 ± 32 vs. 958 ± 405mL/kg for (OEG2)2-IP4 and
IP6, respectively, which is generally expected for hydrophilic com-
pounds. The maximum plasma concentration (Cmax) increased
fourfold, the area under the concentration vs. time curve (AUC0–t)
increased sevenfold and the plasma clearance (CL) decreased
ninefold compared to IP6 (Fig. 4b). Subcutaneous (s.c.) adminis-
tration of 10mg/kg (OEG2)2-IP4 resulted in an AUC comparable to
that of 100mg/kg IP6 (AUC0–360= 1197 ± 36 vs. AUC0–90=
1165 ± 76 µMmin), despite the 10-fold difference in doses (Fig. 4c,
d, Supplementary Table 2)45. The mean residence time (MRT)
was longer for (OEG2)2-IP4 compared to IP6 after s.c. (78 ± 5 vs.
45 ± 20min) as well as i.v. (30 ± 3 vs. 14 ± 6min) administrations
(Supplementary Fig. 11).
No significant accumulation occurred following repeated s.c.
administration of 50 mg/kg (OEG2)2-IP4 for 7 days (Fig. 4e).
Moreover, the systemic exposure of the compound after s.c.
administration was assessed in rats with VC (Fig. 4f, Supple-
mentary Table 3). In the presence of cardiovascular calcification,
the plasma exposure of (OEG2)2-IP4 was significantly higher at 4
and 6 h after dosing, but the AUC0–1440 was not statistically
different to the value obtained before the induction of calcifica-
tion (AUC0–1440= 9077 ± 2455 vs. 6049 ± 799 µMmin).
For many drugs, the PK profile depends on the patient’s renal
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an adenine and high-phosphate-diet-induced rat model of
uremia, in which the compound was administered after serum
creatinine levels had increased by fourfold relative to baseline
(Fig. 4g, h). The Cmax after i.v. injection of 10 mg/kg (OEG2)2-IP4
was almost identical to that of healthy controls (43 ± 12 vs. 35 ±
9 μM) but elimination appeared to be modestly slower in the
uremic rats (1.6-fold longer t1/2 and twofold longer MRT)
(Supplementary Table 4), thus resulting in a higher systemic
exposure to the compound (Fig. 4i). Similar results were observed
following s.c. administration (Supplementary Table 5). Forty
percent of the intact (OEG2)2-IP4 dose was recovered in the urine
of healthy rats, suggesting additional clearance modalities (Fig. 4j).
The protein-bound fraction of (OEG2)2-IP4 in healthy human
plasma was 58% and 42%, respectively, calculated over total
measured concentrations of 2.8 and 27.5 µg/mL (i.e., 4 and
39.5 µM, respectively), suggesting a potential saturation of the
binding sites at high concentrations.
One potential side effect of inositol phosphate-based drugs is
toxicity due to chelation of ionized serum calcium. In a previous
study, a reduction in serum calcium levels by 17% was observed
in uremic rats after 4 h i.v. infusion of 50 mg/kg IP645. No
significant lowering of serum calcium was evident after admin-
istration of 50 mg/kg (OEG2)2-IP4 in either the acute or sub-
chronic setting (7 days), measured at the tmax of 30 min (Fig. 4k).
In a separate in vitro test using human serum, a significant
difference in decrease of human serum-ionized calcium levels
between (OEG2)2-IP4 and IP6 became evident starting from
600 µM (Fig. 4l). At 100 µM (OEG2)2-IP4, 96 ± 2% of control
serum-ionized calcium was measured.
The potential off-target activity of 10 µM (OEG2)2-IP4 was
assessed against a panel of 87 enzymes, receptors, or ion channels
that are used in standard safety pharmacology screens. The
compound did not significantly inhibit or stimulate any of the
respective biochemical assays (Supplementary Table 11).
Efficacy of (OEG2)2-IP4 in a vitamin D-induced model of VC.
Activity of (OEG2)2-IP4 was assessed in an animal model of acute
and severe calcification induced by vitamin D3 overdose, accom-
panied by hypercalcemia, hyperphosphatemia, and increased
plasma creatinine (Supplementary Fig. 12), and reduced body
weight (Supplementary Fig. 13), This model resulted in massive
VC, which was observed primarily along the entire aorta (Sup-
plementary Fig. 14) in the tunica media (Supplementary Fig. 15).
(OEG2)2-IP4, dosed s.c. at 30mg/kg twice daily for 11 days, sig-
nificantly decreased formation of carotid VC as evidenced from
calcium quantification by inductively coupled plasma mass
spectrometry (Fig. 5a), but the decrease in abdominal aorta cal-
cification was not significant (Supplementary Fig. 16). IP6-treated
animals had to be sacrificed ahead of treatment schedule on day
10 vs. day 12, due to the appearance of necrotic skin lesions
(despite maintaining formulation osmolarity and pH within
physiological ranges) (Supplementary Fig. 17). However, calcifi-
cation levels in IP6-treated animals at day 10 were not lower than
those of (OEG2)2-IP4-treated animals at day 12 (Fig. 5a). Inter-
estingly, in this model (OEG2)2-IP4 treatment led to a beneficial
impact on the renal function of vitamin D3-treated animals, as
evident from plasma creatinine levels (Fig. 5c), which occurred in
conjunction with a reduction of renal calcium content (Fig. 5b).
Creatinine levels were significantly decreased in animals receiving
(OEG2)2-IP4 (39.8 ± 6.6 μM) compared to vehicle controls (59.0 ±
7.9 μM), and remained in the healthy range for rats. Plasma cal-
cium and phosphate levels were not impacted by treatment with
(OEG2)2-IP4 (Supplementary Table 6). Given the severity and
resultant variability in calcification burden in this vitamin D3
model, the activity of (OEG2)2-IP4 was assessed in a modified
setup, where VC was induced by oral and less frequent adminis-
tration of vitamin D3 together with a warfarin-supplemented diet.
This model resulted in a robust but milder and less variable
induction of VC, and therefore allowed for a better investigation
of the (OEG2)2-IP4 dose–response. Starting from day 1 of the
vitamin D3 oral administration, animals were treated with s.c.
injections of increasing doses of (OEG2)2-IP4 administered once
or twice daily until day 7. Due to the severe local inflammation
induced by the repeated s.c. injection of IP6 in the previous
experiment, this control was excluded from the present experi-
ment. In two dosing groups, rats lost significantly more weight
than the others compared to day 1, but it was not dose-related
(Supplementary Fig. 18). Mortality rate in the vehicle group was
38% (15/40) and declined to 0% (0/18) in the 2 × 25mg/kg/day
dose group, at which the effect was statistically significant
(Fig. 5d). (OEG2)2-IP4 dose-dependently prevented VC in the
abdominal aorta, as evident from total calcium measurement
(Fig. 5e) and von Kossa staining (Fig. 5f, g). The effect was sta-
tistically significant starting at 2 × 25mg/kg/day and 1 × 12.5 mg/
kg/day with regard to total calcium content and % von Kossa-
positive area, respectively. Moreover, total calcium (Fig. 5h) and %
von Kossa-positive area (Fig. 5i) in the thoracic aorta was sig-
nificantly reduced starting at 2 × 50 and 2 × 25mg/kg/day,
respectively. Intriguingly, and in contrast to the abdominal aorta,
the thoracic aorta did not calcify extensively in all animals, making
differences between treatment groups less evident. A significant
reduction in bulk calcium in the 2 × 25mg/kg/day group was also
evident in more peripheral arteries, i.e., carotid artery (Fig. 5j) and
Fig. 3 (OEG2)2-IP4 abrogates in vitro VSMC calcification and 18F-NaF uptake onto calcified human explants. a, d, f VSMC viability as determined by the
MTS assay compared to medium control. b, c VSMC calcification was induced by high-CaP medium and the effect of cell treatment with IP6 or (OEG2)2-
IP4 was investigated quantitatively by colorimetric analysis of cellular calcium deposition after 5 days control (calcium deposition in mass units in Ctrl.
ranged between 81 and 622 µg Ca/mg protein) (b) and qualitatively by Alizarin Red staining for calcium (c) in a 24-well plate setup compared to medium
control. e, g Same as b but calcium deposition was induced by CPP2- (e) and CPP1- (g) supplemented medium (50 µg Ca/mL), respectively (calcium
deposition in mass units in Ctrl. ranged between 189 and 734 µg Ca/mg protein in e). h TNFα concentration in human macrophage supernatants after
exposing cells to CPP2 (50 µg Ca/mL) and compounds as assessed by immunoassay. High concentrations of IP6, but not (OEG2)2-IP4, precipitated in the
treatment medium as shown in the insets and resulted in significantly increased TNFα levels in supernatants (scale bar= 500 µm). i Macrophage viability
as determined by the MTS assay compared to medium control. j, k, l, m Incubation of severely calcified human femoral arteries (j, l) or human aortic valves
(k, m) with (OEG2)2-IP4 and without (vehicle) resulted in a reduction of 18F-NaF uptake in (OEG2)2-IP4 samples compared with baseline vehicle studies as
evident from the maximum average 18F binding determined by 18F-NaF-PET imaging (j, k) and the maximum intensity projections of collected 18F-NaF-PET
data (l, m). All data are expressed as mean ± s.d. n= 7 (j) and n= 3 (k) biologically independent samples, and from n= 4 (e) and n= 3 (all others)
independent cell experiments. Statistical significance was calculated from an ordinary one-way ANOVA with Tukey’s multiple comparisons test or from an
unpaired Student’s t-test to determine significance between two data sets with *p < 0.05, **p < 0.01, ***p < 0.001 vs. gray bar, #p < 0.001 vs. CPP1, and
§p < 0.001 vs. 100 µM (OEG2)2-IP4.
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femoral artery (Supplementary Fig. 19). Calcification in the heart
and the left kidney was low (<0.2 mg Ca/g tissue and <0.5 mg Ca/g
tissue, respectively) and no differences between treatment groups
were observed. Importantly, (OEG2)2-IP4 did not influence the
calcemic status of the treated animals. Serum levels of ionized
calcium on day 7 were similar after vehicle and (OEG2)2-IP4
(50mg/kg) administration (1.70 ± 0.10 and 1.70 ± 0.13 mM,
respectively).
100 10 mg/kg (OEG2)2-IP4(OEG2)2-IP4 IP6
PK parameters, i.v. injection
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Fig. 4 PK studies and serum calcium studies with (OEG2)2-IP4. a, b Plasma concentration profiles (a) and PK parameters (b) of (OEG2)2-IP4 (n= 3) and
IP6 (n= 6) in healthy rats following the bolus i.v. injection of 10 mg/kg of compound. c, d Plasma concentration profiles (c) and pharmacokinetic
parameters (d) of (OEG2)2-IP4 (n = 3) and IP6 (n = 4) in healthy rats following s.c. administration. Dosing of 10mg/kg IP6 s.c. resulted in plasma
concentrations below the lower limit of quantification (i.e., 772 nM). e Plasma concentrations after acute and sub-chronic treatment (7 days of
administration) with s.c. injection of 50mg/kg/day (OEG2)2-IP4 (n = 4). f Plasma exposures following the s.c administration of 50mg/kg/day (OEG2)2-
IP4 in a rat model of vitamin D and warfarin-induced VC (n = 4). A significant difference was evident after 4 and 6 h. g, h Plasma concentration profiles of
(OEG2)2-IP4 in healthy (non-uremic, n= 6) and adenine and high-phosphate-diet-induced calcification rats (n= 6) following the i.v. bolus (g) and s.c. (h)
administration of 10 mg/kg of compound. i Comparison of the AUC0–t of (OEG2)2-IP4 after administering into healthy (n= 6) and adenine and high-
phosphate-diet-induced calcification groups (n= 6) with t= 360min for s.c. and t= 240min for i.v. groups. j Cumulative recovery of (OEG2)2-IP4 from rat
urine after s.c. administration of 10 mg/kg (OEG2)2-IP4 into healthy rats (n= 5 at 2 h, n= 6 at 8 and 24 h). k Plasma calcium before and 30min after s.c.
administration of 50mg/kg (OEG2)2-IP4 in an acute and sub-chronic (7 days) setting in healthy rats (n = 4). l In vitro-ionized human serum calcium with
(OEG2)2-IP4 or IP6 (n= 3). All data are expressed as mean ± s.d. from n animals. Level of significance was derived from unpaired Student’s t-test in l and
non-parametric Mann–Whitney test in i, k; *p < 0.05 vs. no calcification (f) and IP6 (l), respectively; ns= not significant.
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Efficacy of (OEG2)2-IP4 in an adenine-induced model of VC.
Uremia increases the risk for developing VC. Therefore, the effect
of (OEG2)2-IP4 on the development of VC was investigated in a
previously established adenine and high-phosphate-diet-induced
rat model of VC that results in uremia and chronic renal failure66.
Renal failure, and subsequent calcification, was induced by
feeding a high-phosphate-diet regime for a total of 7 weeks, which
also had a low (2.5%) protein content and was supplemented with
0.75% adenine for a period of 4 weeks, starting 2 weeks into the
high-phosphate-diet. (OEG2)2-IP4 was administered via a s.c.-
implanted osmotic pump at doses of 5, 15, or 50 mg/kg/day for
4 weeks, and treatment was initiated 1 week after the start of
adenine supplementation. As opposed to the vitamin D-induced
calcification model, mortality in the adenine and high-phosphate-
diet-induced VC model was low and did not differ significantly
between treatment groups (Supplementary Table 7). Animals in
this model developed severe CKD (Supplementary Fig. 20), which
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Fig. 5 (OEG2)2-IP4 prevents calcification in a vitamin D-induced rat model of VC. Calcification was induced by either s.c. administration of 300,000 IU/
kg/day vitamin D3 for 5 days combined with high-phosphate diet (a–c) or by oral administration of 100,000 IU/kg/day vitamin D3 for 4 days combined
with a warfarin-supplemented diet (d–j). Bulk calcium in the carotids (a) and kidneys (b), and plasma creatinine (c) of vehicle (n= 8 (b), n= 10 (a, c)),
groups treated with twice daily s.c. injections of 30mg/kg (OEG2)2-IP4 (n= 11) or IP6 (n= 5), and sham (n= 7). One rat in the vehicle group died several
hours after first vitamin D3 injection without explanation. Animals in the IP6 group had to be sacrificed 2 days ahead of schedule and no direct comparison
can be made. d Kaplan–Meier survival plot. e, g Calcium quantification (e) and von Kossa-positive area quantitation (g) in the abdominal aorta.
f Representative images of aortic calcifications stained with von Kossa (black) (scale bar= 500 µm). Calcium (h) and von Kossa-positive area (i)
quantification in the thoracic aorta. Calcium quantification in the carotid artery (j). In d, n= 40 for vehicle, n= 12 for 1 × 12 and 1 × 25mg/kg/day, n= 18
for 2 x 25mg/kg/day, and n= 19 for 1 × 50 and 2 × 50mg/kg/day dose groups. In e–j, n= 7 (e–h) and n= 6 (j) for 1 × 12.5 mg/kg/day, n= 8 for 1 ×
25mg/kg/day, n= 14 (i) and n= 15 (e–g, j) for 1 × 50mg/kg/day, n= 18 for 2 × 25mg/kg/day, n= 16 for 2 × 50mg/kg/day dose groups, n= 24 (g) and
n= 25 (e, h–j) for vehicle. All data are presented as mean ± s.d. from n animals. Statistical significance was derived from non-parametric Kruskal–Wallis
and multiple comparison was performed by Mann–Whitney test with Bonferroni correction, with *p < 0.05, **p < 0.01 and ***p < 0.001 vs. vehicle.
Comparison of survival was performed by Mantel–Cox test.
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Fig. 21). No significant difference in the level of renal failure and
body weight loss was observed between the different treatment
groups, with the exception of creatinine at week 3 and serum
phosphate at sacrifice in the 15 mg/kg/day group (Supplementary
Fig. 20).
There was a trend in a dose-dependent reduction of bulk
calcium in (OEG2)2-IP4-treated animals compared to vehicle in
the abdominal aorta, which is especially prone to calcify in this
model, with a significant effect when comparing the highest dose
(50 mg/kg/day) to the lowest dose (5 mg/kg/day) (Fig. 6a). The
inhibitory effect of (OEG2)2-IP4 on heart calcifications was
significant starting at 15 mg/kg/day (Fig. 6b). The compound’s
activity was also evident following von Kossa staining (Fig. 6c) on
the thoracic part of the aorta, and quantification of the von
Kossa-positive area (Fig. 6d). Treatment with (OEG2)2-IP4 at
50 mg/kg/day significantly reduced calcification compared to
vehicle (2.72 ± 5.97 vs. 14.50 ± 15.11% von Kossa-positive area),
and also compared to 5 and 15 mg/kg/day groups (Supplemen-
tary Table 8). In line with this, treatment with (OEG2)2-IP4 at
50 mg/kg/day also prevented calcification in the carotid artery
compared to the 5 and 15 mg/kg/day groups (Fig. 6e). In the
femoral artery, reduction in bulk calcium was insignificant for all
tested groups, likely due to the low level of calcification detected
in the vehicle control (Fig. 6f, Supplementary Table 9). In
agreement with the results of the PK study and the vitamin D-
induced VC model, the calcemic status of the animals was not
influenced by the administration of (OEG2)2-IP4 50 mg/kg/day
for 4 weeks (Supplementary Fig. 20c). The calcium content
derived from isolated serum CPP at sacrifice (Fig. 6g), CPP2
hydrodynamic diameter (Supplementary Fig. 22), and the serum
calcification propensity (T50) measured in sera collected at
sacrifice (Fig. 6h) did not differ between treatment groups.
Tibial bone histomorphometric analysis revealed an unchanged
mineralized trabecular bone area for the various (OEG2)2-IP4
doses tested (Supplementary Fig. 23). However, a distinct increase
in the osteoid area was observed in the treatment groups, which,
in the presence of an intact osteoblast number/activity, points





























































































































































Vehicle 5 15 50
(OEG2)2-IP4 (mg/kg/day)
Vehicle 5 15 50
(OEG2)2-IP4 (mg/kg/day)
Vehicle 5 15 50
(OEG2)2-IP4 (mg/kg/day)
Vehicle 5 15 50
(OEG2)2-IP4 (mg/kg/day)
Vehicle 5 15 50
(OEG2)2-IP4 (mg/kg/day)





Fig. 6 (OEG2)2-IP4 dose-dependently prevents calcification in an adenine diet-induced rat model of VC. a, b, e, f Quantification of total calcium in the
abdominal aorta (a), the heart (b), the carotid arteries (e), and the femoral arteries (f). c Representative pictures of calcification in the thoracic aorta
stained positive with von Kossa (black) in the different treatment groups (scale bar= 500 µm). d Von Kossa-positive area quantitation in the thoracic
aorta. g Calcium content in CPPs collected from animal sera at sacrifice. h T50 derived from animal sera collected at sacrifice. Results are presented as
mean ± s.d. from n animals, with n= 11 for vehicle, n= 12 for the 5 mg/kg/day dose group, and n= 11 for the 15 and 50mg/kg/day groups. N= 10 for
vehicle in e and h, and for 50 mg/kg/day in e. Statistical significance was derived from non-parametric Kruskal–Wallis test and multiple comparison was
performed by Mann–Whitney test with Bonferroni correction; *p < 0.05 vs. vehicle, #p < 0.05, ##p < 0.01 vs. 5 mg/kg/day, and §p < 0.05, §§p < 0.01 vs.
15 mg/kg/day.
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mineralization (Supplementary Fig. 24). As both osteoblast and
osteoclast morphology were not impacted (Supplementary Fig.
25), this observation suggests that (OEG2)2-IP4 may not exert
cellular toxicity, and that the effect on mineralization of growing
bone is probably due to a passive adsorption effect. In order to
investigate the 3D bone structure, micro-computed tomography
(µCT) analysis was performed, revealing the mineralized
trabecular bone structures to be better preserved in the
(OEG2)2-IP4-treated animals compared to vehicle-treated ani-
mals (Supplementary Fig. 26, Supplementary Table 10). The low
volume of distribution of (OEG2)2-IP4 observed in the PK study
also suggests that only little compound leaves the circulation, and
hence is available to interact with bone.
Discussion. Cardiovascular disease remains the leading cause of
death in the world despite significant advances in the develop-
ment of therapies addressing classical risk factors such as high
cholesterol, hypertension, and diabetes, combined with improved
awareness of the negative impacts of obesity and smoking. This
highlights the importance of investigating different strategies to
combat cardiovascular diseases. One largely unexplored target for
pharmacological intervention is VC, despite the fact that it has
consistently been linked to poor clinical outcomes8. In fact, the
coronary calcification score is the strongest predictor of coronary
events in asymptomatic patients67. Certain high-risk populations
particularly prone to VC have been identified, such as CKD
patients for which the extent of VC and risk of cardiovascular
disease increase dramatically as renal function declines68.
In the present study, a series of inositol phosphate derivatives
were examined for their potential to inhibit VC. Screening for
modifications both in the number and size of OEG moieties on
myo-inositol phosphates led to the identification of (OEG2)2-IP4
as a potent inhibitor of VC. (OEG2)2-IP4 displayed activity in the
high nanomolar range in the competitive 18F-NaF CPP-binding
assay, and prevented the growth of nascent CPPs, their transition
into the crystalline phase, and calcification of VSMC monolayers
in the low micromolar range. Conversely, IP6 was associated with
mid-micromolar activity or a lack of dose–response in these
assays. As opposed to (OEG2)2-IP4, IP6 did not stabilize CPP in
their primary state and led to the formation of CPP2s, which are
hypothesized to initiate pathological response29,30.
In the case of the CaP-induced VSMC calcification model, the
(OEG2)2-IP4 possibly acts in multiple ways to prevent calcifica-
tion. Matrix vesicles secreted by VSMCs under pro-calcifying
conditions form the first nidus for mineralization and chemi-
sorption of (OEG2)2-IP4 onto such nidi may result in crystal
growth inhibition57. Potential intracellular effects, although
unlikely due to the compound’s hydrophilicity and charge
making it difficult to diffuse through cell membranes, cannot be
excluded and should be further investigated.
(OEG2)2-IP4 was efficacious in both adenine and high-
phosphate-diet-induced, and vitamin D-induced rat models of
VC, and displayed dose–response in vitro as well as strong in vivo
activity without affecting serum calcium levels. Importantly,
(OEG2)2-IP4 exhibited superior activity and prolonged plasma
exposure compared to IP6 following bolus i.v. and s.c. admin-
istration, the latter of which opens the possibility of therapeutic
use in a chronic and ambulatory setting. The PK data show that
after s.c. injection plasmatic concentrations above the IC50 were
achieved for at least 4 h vs. 12 min for IP6 (Fig. 4c), which partly
explain the higher efficacy achieved with (OEG2)2-IP4. Moreover,
to our knowledge, this is the first study showing that a
pharmacological treatment can impact the 18F-NaF-PET signal
in the context of VC, and it may therefore serve as a useful tool
for pharmacodynamic read-outs in pre-clinical and early stage
clinical trials, given the growing evidence of its value as a
predictive marker for calcification progression33,34,69.
The differences in activity between (OEG2)2-IP4 and IP6 are
unlikely to be mediated solely by steric hindrance of the OEG
moieties, as the ethylene glycol chain length is short compared to
what is typically used for nanoparticle coating (0.1 vs. 2–5 kDa)47.
The observation that IP6 is a stronger chelator of soluble ionic
calcium than (OEG2)2-IP4, but a weaker inhibitor of calcification,
leads to the hypothesis that an equilibrium exists between binding
to soluble and solid forms of calcium. Therefore, the reduced
charge density of (OEG2)2-IP4 may decrease its binding to soluble
ionic calcium (present in large excess in biological fluids)
rendering it more available for binding to solid forms of calcium.
The OEG chains may prevent stacking and precipitation of
inositol phosphate–calcium complexes and hence further con-
tribute to reducing mineral accretion.
This mechanism of action is possibly similar to that of
extracellular matrix and serum proteins that contain acidic and
phosphorylated residues in order to function as exquisite
regulators of biomineralization32,70. Our observation is in line
with the structural basis of calcification inhibition by fetuin-A,
where surface binding of calcium is mediated by four negatively
charged amino acids on the extended β-sheet of domain D1 that
occupy phosphate positions on the face of apatite crystals71.
It can be hypothesized that (OEG2)2-IP4 acts by stabilizing
CPP2 particles and reducing their uptake by VSMCs and
subsequent calcium overload, which may cause downstream
procalcific and pro-inflammatory events24,30. Chronic exposure
to CPPs, e.g., when clearance becomes overwhelmed as in CKD, is
a likely driver of VC24. CPPs were found to be present in serum
from high-phosphate-diet-fed rats with adenine-induced renal
failure72. By stabilizing CPPs, (OEG2)2-IP4 may aid mineral
clearance from the circulation before VC can ensue. No delay in
T50 was observed when serum samples were tested from the
adenine-induced VC rat model, as (OEG2)2-IP4 was likely to be
already eliminated or bound to existing calcified deposits at the
time of sampling.
Although PEGylation of small molecules with relatively long
PEG chains (>2 kDa) has previously been reported to improve
PK, it was unexpected to discover that conjugation with only two
ethylene glycol repeating units was sufficient to increase systemic
exposure73. The prolonged plasma half-life of (OEG2)2-IP4
compared to IP6, observed in healthy animals, is likely due to
the enhanced metabolic stability of (OEG2)2-IP4. Forty percent of
the intact compound was recovered in the urine, suggesting
additional routes of elimination, such as hepatic clearance and
degradation in plasma that may result in dephosphorylated
metabolites of (OEG2)2-IP4. Plasma exposure of (OEG2)2-IP4 was
somewhat extended in adenine and high-phosphate-diet-fed
animals compared to healthy controls. This effect is seen for
many active pharmaceutical ingredients, and can be rationally
explained by the decreased renal clearance. In contrast, the
plasma level of IP6 has been reported to be decreased in uremic
rats45, possibly due to increased enzymatic metabolism in the
state of uremia, which for (OEG2)2-IP4 may be counterbalanced
by its higher stability.
Since the OEG polymer shows little toxicity, is highly water
soluble and eliminated from the body intact via the kidneys
(PEGs < 30 kDa), and IP6 has previously been administered to
patients displaying acceptable safety and tolerability43, the
likelihood of observing serious toxic side effects with this
chemical entity is low.
In the present study, we observed an effect of (OEG2)2-IP4 on
bone osteoid area. However, it was seen in a CKD/VC rat model
in young animals with open growth plates and rapid bone growth
that presents a dramatically increased bone turnover with chaotic
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bone mineralization, making the rats particularly vulnerable to an
imbalance between excessive osteoid deposition, subsequent
mineralization, and bone resorption74. Therefore, this model
does not accurately reflect the low to mildly increased bone
metabolism in the majority of CKD patients75. On the other
hand, (OEG2)2-IP4 treatment prevented trabecular bone loss
inherent to CKD as could be deduced from 3D-structure analysis
of mineralized bone. This may be due to inhibition of osteoclastic
adhesion to mineralized bone, which in turn would result in
reduced osteoclastic activity. Further experiments are required to
investigate the effect of (OEG2)2-IP4 on bone mineralization.
In summary, this study identified (OEG2)2-IP4, a functiona-
lized myo-inositol phosphate and provided early proof-of-concept
on the applicability of (OEG2)2-IP4 as a potentially universal
inhibitor of pathological soft tissue calcification. Our data
strongly support a mechanism of action in which growth of VC
is hampered by electrostatic interactions of (OEG2)2-IP4 at the
level of nano-, micro-, and macrocalcifications, while preserving
calcium and phosphate homeostasis. Based on its mechanism of
action, (OEG2)2-IP4 may hold great promise in directly targeting
the end product of the VC process (i.e., hydroxyapatite growth
and deposition) in a range of disorders in which VC leads to
impaired cardiovascular function. Ultimately, this work warrants
the further development of (OEG2)2-IP4 (i.e., INS-3001)76,77 in
order to generate clinical evidence of its therapeutic potential for
the benefit of patients.
Methods
Compounds. Synthesis of (±)-OEG12-IP5, (OEG2)2-IP4, and (OEG7)3-IP3 are
described in detail in the Supplementary Information 3.1. (OEG2)3-IP3 as bis-
magnesium salt and (OEG2)2-IP4 as tetra-sodium salt were purchased from Chi-
mete Srl (Tortona, Italy). All other oligoethyleneglycol (OEG) derivatized inositol
phosphates as listed in Supplementary Table 12 were purchased as sodium salt
from Biosynth AG (Thal, Switzerland). Identify and purity was verified by 1H, 31P-
NMR (Appendix NMR Spectra), 13C NMR, and 1H,1H-DQF-COSY and ESI-MS
(Appendix ESI-MS Spectra).
Control compounds were myo-inositol hexakisphosphate (IP6, dodecasodium
salt, P-6700, Biosynth AG), Ins(1,2,3,5,6)P5 (IP5, 10008453), Ins(2,3,5,6)P4 (IP4,
10008455), Ins(1,4,5)P3 (IP3, 10008205), and Ins(2,4)P2 (IP2, 10008419) (sodium
salts, Cayman Chemical, Ann Arbor, MI, USA), myo-inositol (57570, Fluka
Analytical, Buchs, Switzerland), alendronate (A2456), and etidronate (D4159) (TCI
Deutschland GmbH, Frankfurt, Germany), myo-inositol trispyrophosphate (ITPP,
I666020, Toronto Research Chemicals, Toronto, ON, Canada), sodium
pyrophosphate (PPi, AB118827, ABCR, Karlsruhe, Germany), magnesium citrate
(63067, Fluka Analytical), and PEG-alendronate, which was synthesized as
described previously48.
In vitro screening assay. The screening assay was performed as described pre-
viously22. In brief, pooled human serum (H4522, Sigma-Aldrich) stored at −20 °C
was thawed at 37 °C, centrifuged (10,000 × g, and 4 °C, 30 min) (5427R, Eppendorf,
Switzerland), and sterile filtered (0.22 μm filter, Millipore, Merck KGaA) to remove
potential cryoprecipitates (cleared human serum). The calcium solution was
40 mM CaCl2 (102382, Merck KGaA) in HBS, pH 7.4 (RT) (100 mM HEPES
(H3375, Sigma-Aldrich) and 140 mM NaCl (1734712, Fisher Scientific, Hampton,
NH, USA)). The phosphate solution contained 24.00 mM PO4 resulting from the
combination of 19.44 mM Na2HPO4 (28026.292, VWR Chemicals, Radnor, PA,
USA) and 4.56 mM NaH2PO4 ·2H2O (106346, Merck KGaA) in HBS, pH 7.4 (RT).
All salt solutions and buffers were double sterile filtered (0.22 µm) and pre-warmed
to 37 °C prior to use. Calcium solution, serum, phosphate solution, and test
compounds in Milli-Q water were mixed together at a volume ratio of 5:8:5:2 in a
96-well plate (Costar 96-well plate, clear, flat bottom, 3370, Corning Life Sciences,
Corning, NY, USA) with 1 min shaking after each addition to a total volume of
200 µL per well. This resulted in a final concentration of 10 mM calcium and 6 mM
phosphate. The plate was sealed with an adhesive film and the absorption at
550 nm was measured every 3 min with 1 min in-between shaking for a total of 300
cycles at 37 °C using the infinite M200 microplate reader (Tecan, Männedorf,
Switzerland). An A550 vs. time graph was generated and T50 (min) (time at half-
maximum transition from CPP1 to CPP2) values were derived by sigmoidal curve
fit using Prism 8 (nonlinear regression in the log(agonist) vs. response–variable
slope (four parameter mode) using the robust fit fitting method, GraphPad Soft-
ware, San Diego, CA, USA). Activities between compounds were compared by
generating a T50 (min) vs. concentration (µM) graph, calculating nonlinear
regression and deriving the concentration required to delay T50 to 350 min (c350)
using a standard equation for the dose–response curve, Eq. (1), whereby x=
[compound], y= time (min), bottom= baseline response, top=maximum
response, T50= [drug] that leads to half-maximum response, and the hill slope is a
factor that describes the steepness of the curve.
y ¼ bottomþ top bottomð Þ
1þ T50x
 hillslope : ð1Þ
Next, (OEG2)2-IP4, (OEG11)2-IP4 and IP6 at c350 concentration (5.1, 3.8, and
32.9 µM, respectively) were incubated in enzymatically active human serum, used
within 24 h after collection, at 37 °C for 0 and 4.5 h. Human serum was purchased
from Blutspende Zurich (Schlieren, Switzerland), following a formal application for
order of products for laboratory and research purposes, based on the valid Swiss
law of Human Research (HMG). Subsequently, samples were assayed in the
screening assay (vide supra). T50 values were derived and the decrease of T50 (ΔT50)
of a sample incubated in enzymatically active serum for 4.5 h in comparison to 0 h
was reported. Four independent assays using purchased serum from four healthy
human donors were performed.
Phytase assay. The enzyme 3-phytase from Aspergillus niger was purified from
Natuphos® (BASF, Ludwigshafen, Germany) as described previously78 and aliquots
at 4.64 mg/mL were stored at −80 °C until use. Test compounds at 15 µM were
incubated with 23.2 µg/mL of 3-phytase in 10 mM Tris (pH 7.4, RT) (T1503,
Sigma-Aldrich) at 37 °C. Phosphate hydrolysis was monitored over 24 h by spec-
trophotometric quantification of hydrolyzed phosphate using the ammonium
molybdate malachite green method as described previously79.
Calciprotein particles. In vitro CPPs were prepared as described previously61. In
brief, saline (140 mM NaCl), cleared human serum, phosphate solution, and cal-
cium solution were combined at a volume ratio of 2:8:5:5 to a final volume of
30 mL in a 50 mL falcon tube (TPP, Trasadingen, Switzerland) with mixing by
inversion after each addition. All salt solutions and buffers were double sterile
filtered (0.22 µm) and pre-warmed to 37 °C prior to use. The mixture was incu-
bated with continual slow mixing on a rotator (240 rotations/min, KS 130 basic
orbital shaker, IKA, Germany) at 37 °C (WTB Binder, Germany) for 1 h for CPP1
or 14 h for CPP2 formation, respectively. Subsequently, 2-mL aliquots were sub-
jected to centrifugation (20,000 × g, 4 °C, 2.5 h). The resultant pellets were washed
twice with ice-cold HBS, and resuspended by thorough pipetting in 200 μL HBS at
37 °C. The CPP suspensions were pooled and centrifuged (1000 × g, RT, 10 min) to
pellet large aggregates, and the supernatant (CPP suspension) was collected. An
aliquot thereof was dissolved in 0.1 M HCl and CPP calcium was quantified using a
calcium colorimetric assay (MAK022, Sigma-Aldrich) and adjusted to 1 mg Ca per
mL with 100 mM HBS (pH 7.4 (RT)). The CPP suspensions were either used
directly or were snap frozen in liquid nitrogen and stored at −80 °C until further
use and up to a maximum of 2 months, during which CPP stability was confirmed
by DLS.
TEM and selected area electron diffraction. CPPs were prepared (vide supra)
and TEM was performed similar to previous reports71. Additionally, CPP samples
were prepared plus (OEG2)2-IP4 or IP6. Compounds were added at a final con-
centration of 100 μM after combining mineral solutions and serum to initiate CPP
formation and the mixture was incubated for 14 h. Herein, cell culture grade 50
mM HEPES (1 M HEPES, 5630056, Thermo Fischer Scientific) was used for
washing steps, to avoid high solvent and particle background in TEM. In brief,
CPPs at 0.5 mg calcium/mL were drop-casted onto a copper grid, 300 mesh,
covered with a continuous 8-nm-thick carbon film. The TEM data were collected
with an FEI Tecnai F30 FEG TEM operated at 300 kV acceleration voltage and
equipped with a Gatan 749 MultiScan CCD camera (Thermo Fischer Scientific).
The bright-field images were collected at ×39,000 magnification using a 10-μm
objective aperture. To assess the crystallinity of the sample selected area diffraction
patterns were collected in parallel at a camera length of 300 mm. The radii of the
rings in the diffraction pattern were measured (1/nm) and the associated inter-
planar d-spacings (nm) were calculated.
X-ray powder diffraction. CPPs were prepared as described above. Herein, cell
culture grade 50 mM HEPES was used for washing steps to avoid NaCl background
signals. Neat CPP pellets were analyzed on a Stoe IPDS II (Stoe & Cie, Darmstadt,
Germany) with an image plate detector, Cu-Kα radiation (λ= 1.54186 Å), graphite
monochromator, fiber optics, and a modified sample holder (in-house) for trans-
mission powder diffractometry.
Dynamic light scattering. The particle hydrodynamic diameter and polydispersity
index of CPPs were assessed by DLS of samples diluted to 0.5 mg Ca/mL in
100 mM HBS (pH 7.4, RT) in a total volume of 500 µL at 25 °C using a DELSATM
Nano C Particle Analyser (Beckman coulter, Brea, CA, USA). All size measure-
ments were carried out at a fixed scattering angle of 165° and the cumulant method
was used to report the measured particle size.
Human serum studies were performed under sterile conditions at 37 °C as
described previously29. In brief, pre-warmed (37 °C) solutions of saline, cleared
serum, phosphate solution, and calcium solution were combined under sterile
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conditions in a volume ratio of 2:8:5:5 to induce CPP formation. For the pre- and
post-setup, (OEG2)2-IP4 or IP6 in Milli-Q water were added to a final
concentration of 3, 10, 30, and 100 μM before and after the addition of phosphate
and calcium solution, respectively. For serum background measurements, saline,
human serum, and 100 mM HBS (pH 7.4 (RT)) were combined in a volume ratio
of 2:8:10. For compound background measurements, (OEG2)2-IP4 or IP6 in Milli-
Q water were added to a final concentration of 30 and 100 μM to the serum
background samples. The mixtures were incubated with continual slow mixing on
a rotator (240 rotations/min, IKA KS 130 Basics Orbital Shaker) at 37 °C. After 1, 3,
and 5 h of incubation, 500 µL aliquots were drawn under sterile conditions to
prevent microorganism growth contamination and subjected to DLS analysis at
37 °C. For each experiment, three replicates were produced and a single
measurement per sample and time point was performed.
DLS analysis of CPPs induced in serum samples collected from in vivo adenine-
induced VC studies and stored at −20 °C was performed as described for human
serum samples and CPP hydrodynamic diameter development was monitored by
hourly DLS measurements.
In all DLS experiments, the cumulant hydrodynamic diameter and cumulant
polydispersity index from three consecutive measurements was presented unless
stated otherwise.
Cell cultures. All cells were cultured at 37 °C in a humidified atmosphere with 5%
CO2 and were tested for mycoplasma contamination after putting cells into culture
and subsequently monthly using the MycoAlertTM Mycoplasma Detection Kit
(Lonza, Basel, Switzerland). All cell culture experiments in 24- and 96-well plates
(TPP Tissue Culture Test Plate, Techno Plastic Products AG, Trasadingen, Swit-
zerland) were performed in two- and six-well replicates, respectively, and were
repeated independently three times using different batches of CPP2 and test
compounds, unless stated otherwise.
Primary human VSMCs (C-12533, PromoCell, Heidelberg, Germany) were
cultured according to the manufacturer's guidelines in SMC-2 culture medium (C-
22062, PromoCell) and used up to passage 7. For calcification experiments cells
were seeded onto 24-well plates (TPP) at a density of 20,000 cells/well and left to
attach for 48–72 h. Complete medium was M199 medium (31150022, Thermo
Fischer Scientific), supplemented with 10% v/v FBS (10270106, Thermo Fisher
Scientific, Waltham, MA), 1% v/v penicillin/streptomycin (15140122, Thermo
Fisher Scientific), and 4 mM L-glutamine (25030024, Thermo Fisher Scientific)80.
Calcification of cell monolayers was induced as described previously81 by treatment
with CPP2-supplemented (50 µg Ca/mL) medium with or without test compounds
(1, 3, 10, 30, and 100 µM) at a volume of 1 mL/well for 48 h at 37 °C, 5% CO2. In a
second assay, calcification was induced similar to previous experiments56 by cell
treatment with or without test compounds (0.01, 0.1, 1, 10, and 100 µM) in
complete medium supplemented with calcium (2.7 mM) and phosphate (2.5 mM)
(CaP medium) at a volume of 1 mL/well for 5 days, and treatment medium was
replaced on alternate days.
Potential particle growth and formation of precipitate in CaP medium alone
(without cells) was assessed by incubating 1 mL of complete medium, CaP
medium, and CaP medium supplemented with 30 µM (OEG2)2-IP4, respectively, in
24-well plates at 37 °C, 5% CO2 for 48 h. At 0, 12, 24, 36, and 48 h, samples were
collected and subjected to pH measurement (pH Elektrode InLab Micro, Mettler
Toledo, Giessen, Germany), DLS analysis (500 µL of undiluted sample, measured at
25 °C), and absorbance measurement at 570 nm. Furthermore, microscope images
were taken at 0 and 24 h (CTR6000, Leica Camera AG, Wetzlar, Germany) using
the following settings: TL-BF, ×25 magnification, A1.00 magnification changer,
exposure time 1.5 ms, 37 °C.
Calcium deposition on cell monolayers was assessed qualitatively by staining for
calcium with 2% w/v Alizarin Red S aqueous solution (pH 4.2) (05600, Fluka
Analytical). Cell monolayers in 24-well plates were washed with PBS (10010015,
Thermo Fischer), fixed in 10% v/v NBF in PBS (F8775, Sigma-Aldrich) for 45 min
at RT, washed with milli-Q water, incubated for 3 min with 300 µL Alizarin Red S
solution, washed with milli-Q, and images were acquired using a Axiovert 35
microscope (Zeiss, Carl Zeiss Microscopy GmbH, Jena, Germany) at ×100
magnification. Calcium quantitation was performed after washing cells with PBS
and then decalcifying cell monolayers with 0.1 M HCl overnight at 4 °C. Acidic
supernatants were centrifuged (10,000 × g, 4 °C, 10 min) and calcium content was
assessed using the calcium colorimetric assay. After decalcification, cell monolayers
were solubilized (0.1 M NaOH and 0.1% w/v sodium dodecyl sulfate (71729,
Sigma-Aldrich)), and protein content was measured using the Micro BCA Protein
Assay Kit (23235, Thermo Fischer).
Occurrence of precipitation in the different treatment groups was assessed
visually by the naked eye and by a microscope (CTR6000, Leica Camera AG) at
×25 magnification at 0 and 24 h (performed once in duplicate).
Human monocytes THP-1 (TIB-202TM, ATCC, Manassas, VA, USA) were
cultured in suspension in Roswell Park Memorial Institute 1640 medium (RPMI
GlutaMAXTM, 72400021, Thermo Fisher Scientific) supplemented with 10% v/v
FBS (complete medium). Cells were passaged according to the manufacturer’s
guidelines and used up to passage 7. For macrophage differentiation, medium was
further supplemented with 100 nM phorbol 12-myristate 13-acetate (PMA, P8139,
Sigma-Aldrich) and THP-1 cells were then treated for 3 days at 37 °C, 5% CO2.
Subsequently, cells were left to rest in complete medium for 24 h before
experimental use. This method was based on previous work82 and concentrations
of 10–200 nM PMA were screened in order to identify the minimum concentration
necessary to obtain a robust differentiation. Differentiation was assessed by
observation of morphology under a bright-field microscope (CTR6000, Leica
Camera AG) at ×200 magnification, and by cell viability as a surrogate for
macrophage attachment to the well bottom.
THP-1 cells were plated at a density of 200,000 cells/well in a 24-well plate,
differentiated as stated above, and subsequently treated with or without CPP2
(50 μg Ca/mL) in complete medium with or without test compounds (3, 10, 30,
100 μM) for 24 h at 37 °C, 5% CO2.
Occurrence of precipitation in the different treatment groups was assessed
visually by the naked eye and by a microscope (CTR6000, Leica Camera AG) at
×25 magnification at 0 and 24 h (performed once in duplicate).
The cell culture supernatants from the cells treated as described above were
collected at the end of the respective treatment. Supernatants were harvested in 1×
cOmpleteTM protease inhibitor cocktail (Roche, Basel, Switzerland), centrifuged
(1000 × g, 4 °C, 10 min), snap frozen in liquid nitrogen, and stored at −80 °C
until use.
Human TNF-α was assayed in cell culture supernatants using commercial
multiplex immunoassay kits (U-Plex of TNF-α (custom-made multiplex plate) and
Human TNF- Kit (K151QWD-1), both from MesoScaleDiscovery, Rockville, MD,
USA), and corrected for total protein content using the Micro BCATM Protein
Assay Kit.
Cell viability was assessed using the MTS assay (CellTiter 96® Aqueous One
Solution Cell Proliferation Assay, G3580; Promega, Madison, WI, USA) according
to the manufacturer’s instructions. Assays using combined treatment of CPPs or
CaP and test compounds were performed in 24-well plates using 20,000 cells per
well and assays using test compounds only were performed in a 96-well plate
format with a seeding density of 10,000 (VSMC) or 50,000 (THP-1) cells per well,
respectively. For controls, cells were treated with respective complete medium only
and results were calculated as % of control.
Triplicate aliquots of CPP2s (20 µg Ca/mL) in 100 μL assay buffer (100 mM
HBS, pH 7.4 (RT)) were incubated for 1 h at RT in the presence of increasing
concentrations of compounds in 50 μL Milli-Q water and 18F-NaF (1 nM) in 50 μL
assay buffer, resulting in a total incubation volume of 200 μL (18F-NaF was
prepared using a FASTlab synthesizer (GE Healthcare, Little Chalfont, UK) and
commercially available 18F-NaF cassettes (GE Healthcare)). Maximum radiotracer
binding was determined by incubating CPP2s with 18F-NaF (1 nM) only. The
reaction was terminated by rapid filtration through a SOLAμ™ SPE plate (HRP 2
mg/mL 96-well plate, 22 μm; Thermo Fisher Scientific). SPE individual column
matrices were washed twice rapidly in assay buffer and radioactivity on the filters
determined by an automatic gamma counter (Wizard2 Gamma Counter, Perkin
Elmer, Waltham, MA, USA). Percentage binding was calculated as maximum
binding of 18F (absence of (OEG2)2-IP4 or IP6) minus measured binding of 18F in
presence of different compound concentrations divided by maximum binding and
multiplied by 100. The compound concentration, where the percentage binding is
reduced by half (IC50) was determined by single site-specific binding model with a
Hill slope of 1. IC50 is the concentration of agonist that gives a response half way
between the bottom and top parts of the curve. 18F-NaF micro-PET/computed
tomography (micro-PET/CT) was employed for ex vivo analysis of (OEG2)2-IP4’s
engagement to target calcified human tissue explants, as described previously54. In
brief, calcified human tissue samples were incubated with (OEG2)2-IP4 (IC90=
8554 nM) or without (vehicle) in 200 mL of human serum (H4522; Sigma-Aldrich)
for 30 min at RT. Subsequently, 18F-NaF was added (100 kBq/mL, equivalent to
approximately 1 nM, derived from previous CPP2 studies where KD of 18F-NaF to
CPP2s was 1 mM) to the incubation medium and the mixture was incubated for
30 min at RT. Following incubations, samples were washed twice in 0.1 M PBS (1
min per wash) and mounted on a Petri dish for micro-PET/CT imaging (nanoPET/
CT, Mediso, Budapest, Hungary). In total, seven samples from the femoral arteries
of three patients with ischemic peripheral disease and three samples from native
aortic valves of three patients undergoing valve replacement surgery were used. All
samples were collected at the time of surgery and stored in 4% paraformaldehyde at
RT until further use. All patients gave their written, informed consent. All
procedures had local ethical approval (06/S0703/110, 12/WS/0227, 09/S0703/118,
and 12/NW/0036). All studies were approved by East and West Scotland Research
Ethics Committees, and all experiments were conducted according to the principles
expressed in the Declaration of Helsinki.
Pharmacokinetics. All PK studies in healthy animals were performed by the
contract research organization Aphad S.r.l. (Milan, Italy). In all studies, compounds
were administered as a salt, and the doses and plasma quantitation refer to the acid
form. PK parameters listed in Supplementary Table 13 were derived from mea-
sured plasma concentrations applying noncompartmental analysis. Concentration
data were extrapolated using the software Analyst™ 6.1 (Applied Biosystems, Foster
City, CA, USA), the area under the plasma concentration vs. time curve (AUC) was
calculated by linear trapezoidal rule using PK solver 2.0 add-in for Microsoft Excel
2007 (available for download in83), and a uniform weight was performed as a first
general approach.
To study PK in healthy animals, male Sprague-Dawley rats (Harlan,
Correzzana, Italy) were housed up to three per cage with free access to water and
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standard chow (pellets 12 mm, global diet 2018 certificate, Mucedola, Srl, Settimo
Milanese, Italy), and submitted to a 12-h light/dark cycle. Animals were
administered i.v. 10 mg/kg of (OEG2)2-IP4 in saline solution i.v. (30 s bolus,
5 mL/kg) and s.c. (5 mL/kg), respectively, in three animals per route and treatment.
Animals were administered 10 mg/kg IP6 i.v. (30 s bolus, 5 mL/kg) in six animals,
and s.c. (5 mL/kg) at 10 and 100 mg/kg in three animals per treatment. PK after
acute and sub-chronic application was studied using four animals per group dosed
with s.c. (5 mL/kg) 50 mg/kg (OEG2)2-IP4 (in saline) a single time or once daily for
seven consecutive days, respectively. Plasma calcium concentration was determined
in pre-dose samples and in t= 30 min samples of both acute and chronic
treatments using the calcium colorimetric assay. Blood samples of 100 µL were
drawn at several time points from the caudal vein, centrifuged at (3000 × g, 4 °C,
10 min) and stored at −80 °C until analysis by liquid chromatography–tandem
mass spectrometry (LC-MS/MS).
To study urinary excretion, six animals were administered s.c. 10 mg/kg of
(OEG2)2-IP4 and two animals served as blank urine controls. Animals were placed
in separated metabolic cages (TECNIPLAST S.p.A. Buguggiate, Italy) right after
dosing, left there for the entire experiment, and urine was collected after 2, 5, 8, and
24 h. At the end of the experiment, cages were washed with 10 mL water and the
washes were collected in separated tubes. Urine samples were centrifuged at 3000 ×
g and 4 °C for 10 min and stored at −20 °C until quantification of (OEG2)2-IP4 by
LC-MS/MS. Recovery (%) was calculated using Eq. (2).
Recovery %ð Þ ¼ OEG2ð Þ2IP4 μgð Þ
dose μgð Þ ´ rat weight kgð Þ ´ 100: ð2Þ
Animals with induced VC. To study PK in rats presenting with VC, plasma
samples were used from a sub-group of the study where calcification was induced
with vitamin D and warfarin treatment. Herein, four animals with manifest cal-
cification were given s.c. 50 mg/kg (OEG2)2-IP4 (5 mL/kg) on day 1 and day 7, with
no drug administration on intermediate days, and plasma samples for PK analysis
were collected and stored at –80 °C until drug quantitation by LC-MS/MS.
To study PK in uremic animals, male Sprague-Dawley rats (Charles River
Laboratories, L’Arbresle, France) were housed two per cage with free access to
water and standard chow (rat/mouse maintenance diet, SSNIFF Spezialdiäten
GmbH, Soest, Germany) and submitted to a 12-h light/dark cycle. Animals were
fed a low-protein (2.5%) diet containing high phosphorus (1.3% phosphorus and
0.7% calcium) and 0.3% adenine to induce uremia (SSNIFF Spezialdiäten GmbH).
Control animals were fed same diet but without adenine. Every 10 days, a sample of
blood was punctured at the tail vein of each animal. Serum and urine creatinine,
calcium, and phosphorus were then assessed using standard colorimetric
biochemistry analysis (Cobas Mira, Roche, Basel, Switzerland). When a fourfold
increase of creatinine was observed compared to control, the rat was considered
uremic and suitable for PK experiments. The method was validated using eight
animals on control- and adenine-supplemented diet respectively. For PK studies,
on the morning of the experimental day, a catheter was inserted in the right carotid
artery under halothane anesthesia. Subsequently, rats were allowed to recover for
3 h and uremic and non-uremic rats, respectively, were assigned to three groups
of six rats each. Balanced groups were obtained by assigning control animals
with comparable body weight, a central PK-influencing parameter. The first
group received 10 mg/kg (OEG2)2-IP4 injected i.v. via the catheter (1 mL/kg of a
10-mg/mL saline solution, pH 6.0), the second received s.c. 10 mg/kg (OEG2)2-IP4
(2 mL/kg of a 5-mg/mL saline solution, pH 6.0), and the third received 10 mg/kg
IP6 injected i.v. via the catheter (1 mL/kg of a 10-mg/mL saline solution, pH 6.0).
Blood aliquots were drawn after drug administration, centrifuged, decanted, and
stored at −80 °C until serum drug quantification by LC-MS, as well as analysis of
serum creatinine, calcium, and phosphorus (Cobas Mira).
Efficacy of compounds in a vitamin D-induced VC model. Male Sprague-Dawley
rats were housed two per cage with free access to water and standard chow and
submitted to a 12-h light/dark cycle. Compounds were administered and doses
calculated using the salt form. Rats were randomly assigned to sham (n= 7),
vehicle (n= 11), (OEG2)2-IP4 (n= 11), and IP6 (n= 5) groups and given a special
diet containing low-protein (2.5%), high phosphorus (1.3%) and normal calcium
(0.7%) (SSNIFF Spezialdiäten GmbH) for 12 days. Cardiovascular calcification was
induced by s.c. injection (1 mL/kg) of 300,000 IU/kg/day of vitamin D3 (vitamin D3
Streuli, cholecalciferol, sol. inj. 300,000 ;U/mL, Streuli Pharma AG, Uznach, Swit-
zerland) from day 1 to day 5. Sham groups were injected with 0.9% NaCl instead of
vitamin D3. Treatment was administered twice daily (second dose given 6 h after
the first) starting from day 1 to day 12 by s.c. injection of (OEG2)2-IP4 (30 mg/kg
twice a day in saline, pH= 6.0), IP6 (30 mg/kg twice a day in saline, pH= 6.0), or
0.9% NaCl (vehicle and sham group). Blood samples of 500 µL were collected on
day 8 by fine needle from the tail vein and at sacrifice on day 12. After animals were
euthanized by exsanguination under deep anesthesia (1–2% isoflurane, until
decrease of the respiratory rate below 5 inspiration/min), the heart, and aorta were
collected for subsequent analysis. Serum creatinine, calcium, and phosphorus were
measured using standard colorimetric biochemistry analysis (Cobas Mira). Cal-
cium tissue content was measured from dried carotids, whole left kidneys, and
abdominal aortas by ICP-MS analysis. Qualitative staining for calcium by the von
Kossa method, as well as hematoxylin and eosin histology staining were performed
on formalin-fixed dissected aortas, as described elsewhere84. Images of the rat
aortic trees were acquired on a Canon 5D MARKIII (Canon, Tokio, Japan)
equipped with a 50 mm lens.
In a subsequent experiment, animals were randomly assigned to six groups and
given a special diet (SSNIFF Spezialdiäten GmbH) containing normal protein
(17.6%), phosphorus (0.7%), calcium (1%), and warfarin (3 mg/g), starting from
day 1 until day 6 of the study. The special diet did not contain vitamin K, therefore,
a small amount of vitamin K1 (1.5 mg/g) was added to prevent lethal bleeding. VC
was induced by oral gavage (4 mL/kg) of 100,000 IU/kg/day of vitamin D3 (D-
CURE, cholecalciferol, 25,000 IU/mL, Leo Pharma, Ballerup, Denmark) on days 1,
2, 3, and 4. Treatment was administered by s.c. injections (5 mL/kg) of vehicle
(saline, pH 7.4, n= 40), 12.5 mg/kg/day (OEG2)2-IP4 (saline, pH 7.4, n= 12),
25 mg/kg/day (OEG2)2-IP4 (saline, pH 7.4, n= 12), 50 mg/kg/day (OEG2)2-IP4
(saline, pH 7.4, n= 19), 25 mg/kg (OEG2)2-IP4 twice a day (saline, pH 7.4, n= 18),
50 mg/kg (OEG2)2-IP4 twice a day (saline, pH 7.4, n= 19), from day 1 to day 7.
The first dose was given simultaneously with the daily vitamin D administration
and the second dose (vehicle, if compound administration was only once a day),
6 h later. On day 8, animals were euthanized by exsanguination under deep
anesthesia (intraperitoneal injection of ketamine 60 mg/kg and xylazin 7.5 mg/kg),
blood and serum samples were collected, and the latter were stored at −80 °C for
further analysis. At sacrifice, the heart, the aorta, carotids, and femoral arteries were
harvested. Total calcium tissue content of the heart, the proximal part of the
thoracic and abdominal aorta, and the left carotid and femoral arteries was
measured by flame atomic absorption spectrometry, performed as described
elsewhere74, and calcium content was expressed as mg of calcium per g of dry
tissue. Qualitative staining for calcium by the von Kossa method was performed on
paraffin-embedded transversal sections of the thoracic and abdominal aorta at
different positions along the vessel and were prepared as described previously74
and images were taken on a Leica DMR microscope (Leica Camera AG) at ×50
magnification. Quantitation was performed by calculating the percentage of the
calcified area on total tissue area using AxioVision image analysis software (Release
4.5, Carl Zeiss Microscopy GmbH) in which the total tissue area and the von
Kossa-positive area were measured after applying two color separation thresholds.
For each animal the average calcified area in percent was derived from calculating
the percentage of calcified area of all thoracic and abdominal paraffin sections,
respectively. For one animal each of group 1 × 50 mg/kg and 1 × 12.5 mg/kg, a
reliable quantification of von Kossa staining of the a. thoracalis (Fig. 5h) and of
bulk calcium in a. carotis (Fig. 5j), respectively, was not possible due to technical
issues during tissue sampling and processing.
Efficacy of compounds in an adenine and high-phosphate diet-induced VC rat
model. Male Wistar rats (Charles River) were housed two per cage with free access
to water and standard chow and submitted to a 12-h light/dark cycle. Compounds
were administered and doses calculated using the salt form. Animals were ran-
domly assigned to four groups of 12 animals each and given a high-phosphate
(1.03%) diet for 2 weeks before starting a special diet to initiate uremia. Uremia/VC
was induced in all animals by freely fed diet containing high-phosphate (0.92%),
low-protein (2.5% instead of 19%), and adenine (0.75%) for 4 weeks. The diet was
again switched to a high-phosphate (1.03%) diet for 1 week, after which rats were
sacrificed.
The first group was treated with vehicle (double distilled (d.d.) water), the
second, third, and fourth groups were treated with daily doses equivalent of 5, 15,
and 50 mg/kg of (OEG2)2-IP4, respectively, in 2 mL d.d. water starting 1 week after
the administration of the adenine diet. Compounds were delivered continuously for
4 weeks via osmotic pumps (type 2ML4; Alzet, Cupertino, CA, USA) implanted
subcutaneously under anesthesia 1 week after the start of the adenine diet. Blood
sampling for serum and plasma at baseline, week 1, and week 3 was performed in
restrained, conscious animals. Animals were sacrificed by exsanguination after
anesthesia (i.p. administration of ketamine 60 mg/kg and xylazin 7.5 mg/kg)
through the retro-orbital plexus. Serum samples were analyzed for creatinine
according to the Jaffe method85, calcium (using flame atomic absorption
spectrometry74), and phosphate (DiaSys Diagnostic Systems, Holzheim, Germany)
concentrations. In serum samples taken at sacrifice, the CPP-associated calcium
was quantified by calculating the difference between total serum calcium (measured
in serum supernatants after centrifugation at 3000 × g, RT, 15 min) and serum
calcium after removing CPPs by centrifugation (16,000 × g and 4 °C for 120 min)26.
In addition, serum aliquots were centrifuged (10,000 × g, 4 °C, 30 min) and T50’s
were determined as described above. CPP size was monitored by hourly DLS
measurements at 37 °C, after spiking cleared serum samples with calcium (10 mM)
and phosphate (6 mM), for a total of 8 h29.
At sacrifice, the heart, the abdominal aorta, left carotids, and femoral arteries
were collected. The presence of calcification in each animal was evaluated on
paraffin-embedded, von Kossa stained sections of the thoracic aorta (as described
previously74), as well as by measurement of the total calcium content in the heart
and vascular tissue samples by flame atomic absorption spectrometry. Von Kossa-
positive area was quantified (AxioVision Release 4.5 software) (vide supra).
Sample size and treatment assignment. Sample size was determined by logistical
and resource considerations (potential for optimal animal housing and handling in
the facility), as well as characteristics of the animal model (e.g., variation in
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calcification degree) and mortality. The sample size was not based on statistical
power considerations, as no prior data were available. Treatments (vehicle vs.
compound treatment) were assigned randomly and both rats and label of treatment
were randomized. Animals that were excluded from analysis are reported in the
corresponding Results section. Although treatments were not blinded for investi-
gators during the study period, all analyses of soft-tissue calcification were carried
out in a blinded way.
Ethical approval. All experiments using animals comply with the relevant ethical
regulations. The PK experiments were carried out in agreement with the Italian
Law D.L.vo 4 marzo 2014, n. 26 and with authorization from the Ministry of
Health, Italy (authorization number 433/2016-PR dated 4 April 2016). The
experiments of the vitamin D (s.c.)-induced VC model were accepted by the
institutional committee for the humane use of animals, Service de la consommation
et des affaires vétérinaires du canton de Vaud, Lausanne, Switzerland (authoriza-
tion number VD3178 dated 11 November 2016). All other animal experiments
were carried out in agreement with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals 85-23 (1996) and were approved by the
University of Antwerp Ethics Committee (2017–83 and 2018–21).
Quantitation of human ionized serum calcium. To assess reduction in ionized
serum calcium, increasing concentrations of test compounds were incubated in
human serum (Human AB serum, off-the-clot, HSER-ABPM; LuBioScience
GmbH, Zurich, Switzerland) at RT and free ionized calcium levels were measured
subsequently by the o-cresolphthalein method using the calcium colorimetric assay.
Compounds characterization with NMR, high-resolution mass spectrometry,
and high-performance liquid chromatography–ultraviolet absorbance (UV)
detection. Compounds were characterized by 1H-NMR and 31P-NMR, 1H COSY
(400MHz, D2O; Bruker Avance III HD, Bruker BioSpin). Exact masses were
determined by high-resolution mass spectrometry (HRMS) (electrospray ionization
(ESI)-quadrupole-time-of-flight tandem mass spectrometry) (Bruker maXis; Bru-
ker Daltonics, Billerica, MA, USA) in acetonitrile (ACN)/water (1:1 v/v). HRMS
was calibrated using dedicated Tunemix ESI-TOF (positive polarity) (Agilent,
Santa Clara, CA, USA) as reference mass list, the calibration spectrum +MS,
0.10–1.43 min, and enhanced quadratic calibration mode (only mass accuracy
values with an error within ±3 ppm were considered). Purity of the optically active
benzylated precursors, given the full conversion of the final hydrogenolysis step,
was assessed by high-performance liquid chromatography (HPLC) 1260 Infinity
with UV detection (λ= 210 nm) (Agilent Technologies, Santa Clara, CA, USA)
using a Phenomenex Synergi Hydro-RP80A 250 × 4.6 mm, 4 µm (Phenomenex,
Torrance, CA, USA). Compounds were dissolved at 1 mg/mL in MeOH, the
injection volume was 5 µL, mobile phase A was Milli-Q water, and mobile phase B
was ACN (+0.1% v/v formic acid). Gradient program was t= 0 min: A/B (70:30 v/
v); t= 10 min: A/B (5:95 v/v); t= 30 min: A/B (5:95 v/v), and flow rate was 1 mL/
min. Only compounds with >96% purity were considered for further experiments.
For the compound stress test, 20.25 mg (OEG2)2-IP4 in 700 µL D2O was
incubated at 37 °C and stability was monitored by 1H-NMR and 31P-NMR
spectroscopies for up to 6 weeks.
Compound quantitation by LC-MS/MS. Plasma samples of (OEG2)2-IP4 and IP6
were analyzed on an ultra-fast liquid chromatography (UFLC) Shimadzu AC20
(Shimadzu) instrument coupled with an API 4500 Triple Quadrupole AB Sciex
(Sciex, Danaher Corporation, Washington, DC, USA) mass spectrometer. For the
LC part, mobile phase A was 10 mM NH4HCO3 in water (pH 8) for (OEG2)2-IP4
and 50 mM for IP6, mobile phase B was MeOH and injection volumes of 3 and
5 μL were used for (OEG2)2-IP4 and IP6, respectively. The column used for
(OEG2)2-IP4 was Kinetex C8 50 × 2.1 mm, 2.6 μm 100 A (Phenomenex, Basel,
Switzerland), thermostated at 35 °C. The column used for IP6 was Xterra MS C18
50 × 4.6 mm, 2.5 μm (Waters, Milford, MA, USA) thermostated at 40 °C. Different
gradient programs were applied for (OEG2)2-IP4 (Supplementary Table 14) and
IP6 (Supplementary Table 15) using a mobile phase flow rate of 0.3 mL/min. MS/
MS parameters (multiple reaction monitoring (MRM) acquisition) for (OEG2)2-
IP4 and IP6 together with internal standard (IS) are reported in Supplementary
Tables 16 and 17, respectively. The source was working in electrospray negative
ionization (ESI−) mode for both compounds with the following ESI parameters:
for (OEG2)2-IP4, capillary temperature 400 °C, Gas1 50, Gas2 40, CUR 40, spray
voltage −4500 V, CAD medium; for IP6, capillary temperature 350 °C, Gas1 30,
Gas2 40, CUR 30, spray voltage −4500 V, CAD medium, DP −19, EP −8.
Quantitation was carried out as total ion current on the sum of the MRM tran-
sitions. Calibration curve and quality control samples were prepared by adding
5 μL of working solution to 45 μL rat blank plasma and precipitating plasma protein
by addition of 50 μL of 0.1% v/v trichloroacetic acid in water/MeOH (1:1 v/v)
including IS (i.e., 1 μg/mL of OEG11-IP5 for (OEG2)2-IP4, no IS for IP6). Samples
were agitated 5 min on a 600 × g orbital shaker and centrifuged (16,000 × g, 5 °C,
20 min). Supernatants (25 μL) were then transferred into a plate with 25 or 50 μL of
1% w/v NH4OH in water for (OEG2)2-IP4 and IP6, respectively. Samples were then
subjected to LC-MS/MS. Rat PK samples were prepared for analysis in an analogous
manner as done for spiked samples. The lower limit of quantification (LLOQ)
and detection (LOD) in rat plasma for (OEG2)2-IP4 were 25 and 10 ng/mL,
respectively. The upper limit of quantification (ULOQ) and detection was
5000 ng/mL. For IP6, LLOQ, LOD, and ULOQ were 500, 250, and 25,000 ng/mL,
respectively.
The bioanalytical method for (OEG2)2-IP4 in rat plasma was further
optimized, qualified, and applied to the comparative PK study in adenine and
high-phosphate diet-induced VC vs. vitamin D-induced VC animals. The LC-
MS/MS analyses were carried out using a Dionex Ultimate RSLC ultra-high-
pressure liquid chromatography (UHPLC) system (Thermo Fisher Scientific)
coupled with a TSQ QuantivaTM triple quadrupole mass spectrometer. The
samples were stored at 5 °C in the autosampler prior to and during the analyses.
Optimal separation was performed with a Waters (Milford, MA) XBridge BEH
Amide, 2.1 × 50 mm, 2.5 μm maintained at 25 °C, and a flow rate of 0.4 mL/min.
Gradient elution (solvent A, 20 mM ammonium acetate in water (pH 5); solvent
B, ACN) was used according to the program reported in Supplementary
Table 18. The injection volume was 10 µL. MS/MS parameters (MRM
acquisition, cycle time 0.2 s) for (OEG2)2-IP4 are reported in Supplementary
Table 19 and the ESI source, working in negative ionization mode, applied the
following parameters: static spray voltage 3000 V ion transfer tube and vaporizer
temperatures at 400 and 100 °C, respectively; sheath and auxiliary gas (nitrogen)
flow rates at 80 and 3 (arbitrary units). For the quantitative determination in rat
plasma, product ion m/z 158.9 was selected because it provided the best
sensitivity and selectivity. Calibration curve and quality control samples were
prepared by adding 2 μL of working solution to 38 μL rat blank K3EDTA plasma
(Biochemed, Winchester, VA) and precipitating plasma protein by addition of
120 μL of MeOH including internal standard OEG11-IP5. Samples were vortexed
1 min and centrifuged at (22,000 × g, 4 °C, 10 min). Supernatants (90 μL) were
then transferred into a glass vial with insert and injected onto LC-MS/MS
system. Both in adenine and high-phosphate diet-induced VC and vitamin D-
induced VC rat PK samples were prepared for analysis in an analogous manner
as done for spiked samples (assay volume 40 μL). The LLOQ and LOD in rat
plasma for (OEG2)2-IP4 were 50 and 10 ng/mL, respectively. The ULOQ and
detection was 50,000 ng/mL.
Calcium quantitation by inductivity coupled mass spectrometry (ICP-MS).
Calcium tissues’ contents were measured at the Central Environmental Laboratory
(EPFL, Lausanne, Switzerland). Dry tissues (90 °C, overnight) were weighed and
digested by aqua regia overnight at RT, followed by 2 h reflux, after which the
solvent was completely evaporated with a steady flow of nitrogen gas. The dried
samples were then reconstituted and homogenized with nitric acid. Calcium
standards and samples were diluted with nitric acid. Absorbance was recorded
using ICP-OES (Shimadzu ICPE-9000, Shimadzu). Two technical replicates were
measured for each sample. Standard solutions were also included with the
experimental samples for each set of measurements. Tissue concentrations of
calcium were expressed as mg/g of dry tissue.
Statistical analysis. Data analysis, curve fitting, and statistical analysis were
performed with Prism 8. Statistical significant differences between two groups were
calculated using paired or unpaired Student’s t-test. Statistically significant differ-
ences between multiple groups were derived by one-way ANOVA followed by
Tukey’s multiple comparison test. For in vivo data non-parametric testing by
Kruskal–Wallis test followed by Mann–Whitney test with Bonferroni correction
was performed. Normality of in vivo data was assessed using IBM SPSS 24. For the
survival curve Kaplan–Meier analysis was performed and comparison of survival
was done using a log-rank (Mantel–Cox) test. All data are presented as mean ±
standard deviation (s.d.) from n independent experiments, as indicated in each
figure legend and a p value of <0.05 was considered significant.
Data availability
The authors declare that the data supporting the findings of this study are available
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